The critical roles of integrins in thrombosis have enabled the successful development and
clinical use of the first generation of integrin antagonists as represented by abciximab …

Three platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been approved as
adjunctive therapy to decrease the ischemic complications of percutaneous coronary …

Acute thrombocytopenia is a recognized complication of treatment with GPIIb/IIIa inhibitors
whose cause is not yet known. We studied 9 patients who developed severe …

From the discovery of the platelet glycoprotein (GP) IIb/IIIa and identification of its central role
in haemostasis, the integrin GPIIb/IIIa (αIIbβ3, CD41/CD61) was destined to be an anti …

The platelet integrin αIIbβ3 is essential for hemostasis and thrombosis through its binding of
adhesive plasma proteins. We have determined crystal structures of the αIIbβ3 headpiece in …

An integrin found on platelets, αIIbβ3 mediates platelet aggregation, and αIIbβ3 antagonists
are effective antithrombotic agents in the clinic. Ligands bind to integrins in part by …

Integrins mediate the adhesion of cells to each other and to the extracellular matrix during
development, immunity, metastasis, thrombosis, and wound healing. Molecular defects in …

Integrins are bidirectional signaling molecules on the cell surface that have fundamental
roles in regulating cell behavior and contribute to cell migration and adhesion …

The integrin αVβ3 receptor has been implicated in several important diseases, but no
antagonists are approved for human therapy. One possible limitation of current small …

Arginine-glycine-aspartic acid (RGD)–mimetic platelet inhibitors act by occupying the RGD
recognition site of αIIb/β3 integrin (GPIIb/IIIa), thereby preventing the activated integrin from …